PID's Holdings Imply 14% Gain Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2024
0mins
Source: NASDAQ.COM
Invesco International Dividend Achievers ETF Analysis: The Invesco International Dividend Achievers ETF (PID) has an implied analyst target price of $21.89 per unit, indicating a potential upside of 14.36% from its recent trading price of $19.14.
Notable Holdings and Analyst Targets: Key holdings such as National Grid plc, Restaurant Brands International Inc, and Novartis AG show significant upside potential, with target prices suggesting increases of 28.92%, 20.28%, and 19.45% respectively compared to their current share prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 154.140
Low
112.00
Averages
127.75
High
143.00
Current: 154.140
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanguard Research Favors Value and International Stocks in AI Era
- Positive Outlook for Value Stocks: Vanguard's research suggests that U.S. value stocks may outperform tech stocks in the upcoming AI-driven productivity era, with the Vanguard Small-Cap Value ETF achieving approximately 27% returns over the past year, indicating strong market competitiveness.
- International Dividend ETF Performance: The Vanguard International Dividend Appreciation ETF currently offers a trailing 12-month dividend yield of 2.12% and holds 343 international stocks; despite underperforming the S&P 500 over the past five years, its stable dividend payments attract income-seeking investors.
- Opportunities in Small-Cap Stocks: The Vanguard Small-Cap Value ETF, holding 835 small-cap stocks, delivered a 15.9% return in the first half of the year and charges a low expense ratio of 0.05%, providing a diversified investment option for those optimistic about the growth potential of smaller companies.
- International Market Potential: Vanguard's research indicates that future AI gains may flow to international markets, particularly companies in Japan, Canada, and Western Europe, which have a solid foundation for leveraging AI to enhance profitability, potentially yielding significant returns for investors.
See More
Vanguard Sees AI Boosting Value Stocks Over Tech
- AI Investment Outlook: Vanguard's research indicates that the largest future gains from AI may not go to major tech firms but rather to U.S. value stocks and international developed market equities, as these companies are better positioned to leverage AI for enhanced profitability and efficiency, thereby gaining a competitive edge.
- Small-Cap Value ETF Performance: The Vanguard Small-Cap Value ETF (VBR), which holds 835 stocks, achieved a 27.1% return over the past year, outperforming the S&P 500, and charges a low expense ratio of 0.05%, indicating significant growth potential amid rising AI productivity.
- International Dividend ETF Analysis: The Vanguard International Dividend Appreciation ETF (VIGI) consists of 343 international stocks with an 8.4% annualized return over the past decade; despite underperforming the S&P 500, its 2.12% dividend yield remains competitive among peers, appealing to investors optimistic about international markets.
- Market Distribution and Risks: VIGI's portfolio is primarily focused on developed markets, particularly Japan and Canada, and while it has underperformed historically, the potential for AI to enhance profitability in these firms could yield substantial returns for investors in the future.
See More
Comparative Analysis of International Stock ETFs
- Market Coverage Differences: The iShares Core MSCI EAFE ETF (IEFA) focuses solely on developed market stocks outside the U.S. and Canada, tracking around 2,600 stocks, while the Vanguard Total International Stock ETF (VXUS) encompasses both developed and emerging markets with approximately 8,700 stocks, showcasing VXUS's broader global coverage.
- Sector Allocation Comparison: IEFA's top sector allocations are financials (23%), industrials (19%), and technology (12%), whereas VXUS has higher allocations in financials (22%), technology (21%), and industrials (15%), particularly highlighting the significant influence of technology in emerging markets, reflecting VXUS's investment potential in AI and other emerging sectors.
- Portfolio Selection: IEFA is suitable for investors looking to focus on developed markets, while VXUS offers a superior choice for those seeking comprehensive international stock coverage, especially in the context of today's diversified global economy, making VXUS's diversified strategy more appealing.
- Expense Ratio Advantage: Both ETFs boast expense ratios below 0.1%, providing competitive cost-effectiveness; however, VXUS's diversified portfolio may offer higher long-term return potential, particularly given the growth expectations in emerging markets.
See More
Comparison of Core International Stock ETFs
- ETF Fee Comparison: Both the iShares Core MSCI EAFE ETF and the Vanguard Total International Stock ETF feature expense ratios below 0.1%, enabling investors to effectively manage costs when selecting core international equity funds, thereby enhancing long-term investment returns.
- Market Coverage Differences: The iShares Core MSCI EAFE ETF focuses solely on developed markets, holding approximately 2,600 stocks with Japan and the UK accounting for nearly 40%, while the Vanguard Total International Stock ETF encompasses both developed and emerging markets with around 8,700 stocks, offering broader global investment opportunities.
- Sector Allocation Analysis: The iShares Core MSCI EAFE ETF's top sectors include financials (23%), industrials (19%), and technology (12%), whereas the Vanguard Total International Stock ETF has a higher allocation in technology (21%) alongside financials (22%) and industrials (15%), reflecting a greater emphasis on emerging fields like AI.
- Investment Choice Recommendations: For investors seeking comprehensive international stock coverage in a single fund, the Vanguard Total International Stock ETF is the superior choice, while the iShares Core MSCI EAFE ETF is suitable for those focusing exclusively on developed markets, highlighting the applicability of different investment strategies.
See More
Novartis Gene Therapy Itvisma Approved by European Commission
- Gene Therapy Approval: Novartis' gene therapy Itvisma has been approved by the European Commission for children aged two and older with spinal muscular atrophy (SMA), marking its availability across all 27 EU member states as well as Norway, Iceland, and Liechtenstein.
- Innovative Treatment Option: Itvisma is the first approved gene replacement therapy targeting a broad group of SMA patients, designed to replace the survival motor neuron 1 (SMN1) gene, thereby enhancing Novartis' product offerings in the SMA treatment landscape.
- Market Competitive Edge: Together with the existing Zolgensma therapy, Itvisma provides gene replacement therapy options for SMA patients at various stages, from newborns to adults, significantly strengthening Novartis' competitive position in the European market.
- Clinical Research Backing: The approval follows the pivotal STEER study results, which demonstrated Itvisma's statistically significant improvement on SMA disease progression scales, further solidifying Novartis' leadership in muscle disease therapies.
See More
Novartis Receives Approval for Itvisma Gene Therapy
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
See More
Vanguard Research Favors Value and International Stocks in AI Era
- Positive Outlook for Value Stocks: Vanguard's research suggests that U.S. value stocks may outperform tech stocks in the upcoming AI-driven productivity era, with the Vanguard Small-Cap Value ETF achieving approximately 27% returns over the past year, indicating strong market competitiveness.
- International Dividend ETF Performance: The Vanguard International Dividend Appreciation ETF currently offers a trailing 12-month dividend yield of 2.12% and holds 343 international stocks; despite underperforming the S&P 500 over the past five years, its stable dividend payments attract income-seeking investors.
- Opportunities in Small-Cap Stocks: The Vanguard Small-Cap Value ETF, holding 835 small-cap stocks, delivered a 15.9% return in the first half of the year and charges a low expense ratio of 0.05%, providing a diversified investment option for those optimistic about the growth potential of smaller companies.
- International Market Potential: Vanguard's research indicates that future AI gains may flow to international markets, particularly companies in Japan, Canada, and Western Europe, which have a solid foundation for leveraging AI to enhance profitability, potentially yielding significant returns for investors.
See More
Vanguard Sees AI Boosting Value Stocks Over Tech
- AI Investment Outlook: Vanguard's research indicates that the largest future gains from AI may not go to major tech firms but rather to U.S. value stocks and international developed market equities, as these companies are better positioned to leverage AI for enhanced profitability and efficiency, thereby gaining a competitive edge.
- Small-Cap Value ETF Performance: The Vanguard Small-Cap Value ETF (VBR), which holds 835 stocks, achieved a 27.1% return over the past year, outperforming the S&P 500, and charges a low expense ratio of 0.05%, indicating significant growth potential amid rising AI productivity.
- International Dividend ETF Analysis: The Vanguard International Dividend Appreciation ETF (VIGI) consists of 343 international stocks with an 8.4% annualized return over the past decade; despite underperforming the S&P 500, its 2.12% dividend yield remains competitive among peers, appealing to investors optimistic about international markets.
- Market Distribution and Risks: VIGI's portfolio is primarily focused on developed markets, particularly Japan and Canada, and while it has underperformed historically, the potential for AI to enhance profitability in these firms could yield substantial returns for investors in the future.
See More
Comparative Analysis of International Stock ETFs
- Market Coverage Differences: The iShares Core MSCI EAFE ETF (IEFA) focuses solely on developed market stocks outside the U.S. and Canada, tracking around 2,600 stocks, while the Vanguard Total International Stock ETF (VXUS) encompasses both developed and emerging markets with approximately 8,700 stocks, showcasing VXUS's broader global coverage.
- Sector Allocation Comparison: IEFA's top sector allocations are financials (23%), industrials (19%), and technology (12%), whereas VXUS has higher allocations in financials (22%), technology (21%), and industrials (15%), particularly highlighting the significant influence of technology in emerging markets, reflecting VXUS's investment potential in AI and other emerging sectors.
- Portfolio Selection: IEFA is suitable for investors looking to focus on developed markets, while VXUS offers a superior choice for those seeking comprehensive international stock coverage, especially in the context of today's diversified global economy, making VXUS's diversified strategy more appealing.
- Expense Ratio Advantage: Both ETFs boast expense ratios below 0.1%, providing competitive cost-effectiveness; however, VXUS's diversified portfolio may offer higher long-term return potential, particularly given the growth expectations in emerging markets.
See More
Comparison of Core International Stock ETFs
- ETF Fee Comparison: Both the iShares Core MSCI EAFE ETF and the Vanguard Total International Stock ETF feature expense ratios below 0.1%, enabling investors to effectively manage costs when selecting core international equity funds, thereby enhancing long-term investment returns.
- Market Coverage Differences: The iShares Core MSCI EAFE ETF focuses solely on developed markets, holding approximately 2,600 stocks with Japan and the UK accounting for nearly 40%, while the Vanguard Total International Stock ETF encompasses both developed and emerging markets with around 8,700 stocks, offering broader global investment opportunities.
- Sector Allocation Analysis: The iShares Core MSCI EAFE ETF's top sectors include financials (23%), industrials (19%), and technology (12%), whereas the Vanguard Total International Stock ETF has a higher allocation in technology (21%) alongside financials (22%) and industrials (15%), reflecting a greater emphasis on emerging fields like AI.
- Investment Choice Recommendations: For investors seeking comprehensive international stock coverage in a single fund, the Vanguard Total International Stock ETF is the superior choice, while the iShares Core MSCI EAFE ETF is suitable for those focusing exclusively on developed markets, highlighting the applicability of different investment strategies.
See More
Novartis Gene Therapy Itvisma Approved by European Commission
- Gene Therapy Approval: Novartis' gene therapy Itvisma has been approved by the European Commission for children aged two and older with spinal muscular atrophy (SMA), marking its availability across all 27 EU member states as well as Norway, Iceland, and Liechtenstein.
- Innovative Treatment Option: Itvisma is the first approved gene replacement therapy targeting a broad group of SMA patients, designed to replace the survival motor neuron 1 (SMN1) gene, thereby enhancing Novartis' product offerings in the SMA treatment landscape.
- Market Competitive Edge: Together with the existing Zolgensma therapy, Itvisma provides gene replacement therapy options for SMA patients at various stages, from newborns to adults, significantly strengthening Novartis' competitive position in the European market.
- Clinical Research Backing: The approval follows the pivotal STEER study results, which demonstrated Itvisma's statistically significant improvement on SMA disease progression scales, further solidifying Novartis' leadership in muscle disease therapies.
See More
Novartis Receives Approval for Itvisma Gene Therapy
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
See More
